YOU ARE HERE: LAT HomeCollectionsHuman Immuno Deficiency Virus

Human Immuno Deficiency Virus

June 28, 2007 | From Times Wire Reports
A Kazakh court convicted 21 medical workers of having roles in infecting scores of children with HIV. The Shymkent district court gave suspended sentences to five senior health officials, including the district's chief medical officer, according to the ruling by Judge Ziyadinkhan Pirniyaz. Sixteen other medical workers, including nurses and doctors in the city's hospital and clinics, received sentences of up to five years.
June 23, 2007 | From Times Staff and Wire Reports
Pfizer Inc., the world's biggest drug maker, failed to win U.S. approval for maraviroc, the first new type of medicine in a decade to treat HIV, the virus that causes AIDS. Pfizer is working on changes the Food and Drug Administration sought on the product's labeling, the company said Wednesday. Maraviroc is intended for patients who have failed to reduce their levels of HIV with other treatments.
May 31, 2007 | James Gerstenzang, Times Staff Writer
President Bush said Wednesday that he would ask Congress to increase U.S. support for the global fight against HIV/AIDS to $30 billion over five years from the current commitment of $15 billion. The White House estimates the increased spending would treat 2.5 million people, prevent 12 million infections and provide additional care for 12 million people, among them 5 million orphans and other children. In the program's first three years, through March, it helped pay for treatment of 1.
May 9, 2007 | From Times Wire Reports
Former President Clinton announced agreements with drug companies to lower the price of "second-line" AIDS drugs for people in the developing world and to make a once-a-day AIDS pill available for less than $1 a day. The anti-retroviral drugs are needed by patients who develop resistance to first-line treatment and cost 10 times as much as first-line therapy, Clinton said in New York. Nearly half a million will require these drugs by 2010.
April 25, 2007 | From the Associated Press
The federal government should approve a novel drug that targets the cells of HIV-infected patients and not the virus itself, health advisors recommended Tuesday. The 12 advisors unanimously voted to urge the Food and Drug Administration to approve maraviroc, which Pfizer Inc. hopes to sell under the brand name Celsentri. It would represent the first so-called CCR5 receptor antagonist to be sold.
April 21, 2007 | From Reuters
An experimental Pfizer Inc. AIDS pill was effective at suppressing the HIV virus when added to the best available drug regimens, U.S. drug reviewers said in an analysis released Friday. The Food and Drug Administration staff, however, said they would ask an advisory panel that meets Tuesday for advice "regarding the possible need for special labeling as well as whether additional clinical trials should be performed to address particular safety issues."
April 5, 2007 | Jia-Rui Chong, Times Staff Writer
A new AIDS drug that received accelerated federal approval last summer is significantly better at attacking highly resistant HIV than existing drugs, according to a study of 230 patients published Wednesday. Darunavir, part of the decade-old class of drugs known as protease inhibitors, lowered virus levels to the undetectable range in 45% of patients after 48 weeks. By comparison, 10% of patients on other drug regimens showed similar declines.
April 4, 2007 | Jordan Rau, Times Staff Writer
A widely touted law that was supposed to provide medical care for poor, uninsured Californians infected with HIV has yet to be put into practice by Gov. Arnold Schwarzenegger's administration, leaving thousands without the health coverage lawmakers promised more than four years ago. The 2003 law was endorsed by newspapers across the state and championed by activists as the most significant piece of AIDS-related legislation in a decade.
March 31, 2007 | From Times Staff and Wire Reports
HIV-positive women who breastfeed exclusively are less than half as likely to transmit the virus to their babies as women who use a mixture of breastfeeding and formula, South African researchers reported Friday in the medical journal Lancet. Exclusive breastfeeding ordinarily protects the integrity of the intestinal mucosa, which thereby presents a more effective barrier to HIV, they said. It also is associated with fewer breast problems that can cause an increased viral load in breast milk.
March 2, 2007 | Francisco Vara-Orta, Times Staff Writer
A majority of Los Angeles County primary care practitioners are failing to advise their Latino patients -- who are at high risk for HIV infection -- to get tested, according to a UCLA study released Thursday. Only 41% of the 85 surveyed primary care providers -- including doctors, nurses and physician assistants -- had regularly offered advice about sexually transmitted diseases during the six-month period covered in the study, which was conducted in 2004 by the UCLA AIDS Institute.
Los Angeles Times Articles